Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Chronic heart failure; Renal impairment
- Focus Therapeutic Use
- 09 Apr 2018 Planned End Date changed from 30 Mar 2018 to 30 Apr 2019.
- 09 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Oct 2017 Planned End Date changed from 30 Jan 2018 to 30 Mar 2018.